Identification of estrogen (ER), progesterone (PR) and human epidermal growth factor receptor 2 (HER2) receptors as molecular markers and oncogenic drivers for the disease has allowed more accurate stratification of tumours and development of efficacious targeted therapies, leading to significant improvements in the management and outcome of BC patients [1, 2]. This evidence concerns the gene ERBB2 and neoplasm.